ENTPD3: The Potential Drug Target and Biomarker (G956)

Target Name: ENTPD3

NCBI ID: G956

ENTPD3

ENTPD3: The Potential Drug Target and Biomarker

ENTPD3, also known as ectonucleoside triphosphate diphosphohydrolase 3, is a protein enzyme that plays a crucial role in the DNA replication process in eukaryotic cells. It is a key enzyme in the DNA double helix break repair system, which ensures that any errors or mutations in the DNA are promptly repaired to prevent genetic mutations from occurring. ENTPD3 is also involved in the regulation of DNA replication, which is critical for the growth and development of cancer cells.

The discovery of ENTPD3 as a potential drug target and biomarker has significant implications for the treatment of various diseases, including cancer. ENTPD3 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, it has been found to be associated with poor prognosis in cancer patients.

ENTPD3 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. It has been found that individuals with certain genetic mutations, such as those that cause Alzheimer's disease, have lower levels of ENTPD3 in their brains. This suggests that ENTPD3 may be a potential therapeutic target for these diseases.

ENTPD3 is also a potential biomarker for cancer, as its levels are often elevated in cancer cells compared to healthy cells. This suggests that ENTPD3 levels may be a useful diagnostic tool for cancer detection and monitoring.

In addition to its potential therapeutic and diagnostic applications, ENTPD3 is also of interest to researchers because of its unique structure and mechanism of action. ENTPD3 is a large protein that consists of 116 amino acids and has a molecular weight of 13.9 kDa. It has a distinct N-terminal transmembrane domain and a catalytic core domain that is responsible for its catalytic activity.

The catalytic core domain of ENTPD3 is known as the active site, which is the region of the protein that is responsible for catalyzing chemical reactions. This domain has been shown to have a unique structure that allows it to interact with small molecules, such as nucleotides, with high affinity. This interaction allows ENTPD3 to efficiently catalyze the breakdown of eukaryotic DNA double-strands, which is a critical step in the DNA replication process.

ENTPD3 has also been shown to have a unique mechanism of action that allows it to regulate DNA replication in a highly specific and efficient manner. It does this by interacting with the double-stranded DNA at specific sites, which are specific to the DNA template. This interaction allows ENTPD3 to specifically target the double-stranded DNA at these sites and then catalyze the breakdown of the double-stranded DNA at these sites, which results in the formation of a single-stranded DNA break.

In conclusion, ENTPD3 is a protein enzyme that plays a crucial role in the DNA replication process in eukaryotic cells. Its unique structure and mechanism of action make it an attractive target for therapeutic intervention. The discovery of ENTPD3 as a potential drug target and biomarker has significant implications for the treatment of various diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the potential of ENTPD3 as a therapeutic and diagnostic tool.

Protein Name: Ectonucleoside Triphosphate Diphosphohydrolase 3

Functions: Has a threefold preference for the hydrolysis of ATP over ADP

The "ENTPD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENTPD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets